BPMC Blueprint Medicines
- 94.860
- +3.520+3.85%
- 104.000
- +9.140+9.64%
Blueprint Medicines News
Express News | Blueprint Medicines Shares up 10.4% Premarket After Surprise Q1 Profit
Blueprint Medicines Price Target Maintained With a $97.00/Share by Needham
Blueprint Medicines Price Target Maintained With a $97.00/Share by Needham
Express News | Needham Reiterates Buy on Blueprint Medicines, Maintains $97 Price Target
Blueprint Medicines Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/02/2024 -3% Needham → $97 Reiterates Buy → Buy 04/26/2024 30% Stifel $120 → $130 Maintains Buy 04/26/20
Express News | Blueprint Medicines Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Results and Raised FY24 Revenue Guidance
Earnings Flash (BPMC) BLUEPRINT MEDICINES CORPORATION Posts Q1 Revenue $96.1M, Vs. Street Est of $81.4M
07:15 AM EDT, 05/02/2024 (MT Newswires) -- Earnings Flash (BPMC) BLUEPRINT MEDICINES CORPORATION Posts Q1 Revenue $96.1M, vs. Street Est of $81.4M
Blueprint Medicines Raises 2024 AYVAKIT Net Pdt Rev to $390M to $410M Range>BPMC
Blueprint Medicines Raises 2024 AYVAKIT Net Pdt Rev to $390M to $410M Range>BPMC
Express News | Blueprint Medicines Q1 2024 GAAP EPS $1.40 Beats $(1.66) Estimate, Sales $96.116M Beat $80.434M Estimate
Express News | Blueprint Medicines Corp: Ind for Wild-Type Kit Inhibitor Blu-808 on Track for Filing in Q2
Press Release: Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT(R)/AYVAKYT(R) (Avapritinib) Full Year Revenue Guidance
Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT(R)/AYVAKYT(R) (avapritinib) Full Year Revenue Guidance PR Newswire CAMBRIDGE, Mass., May 2, 2024 -- Achieved $92.5 m
Express News | Blueprint Medicines Corp: Raising Guidance to $390 Mln to $410 Mln in Full Year Ayvakit Net Product Revenues
Express News | Blueprint Medicines Q1 Pretax Profit USD 89.316 Million Vs. Ibes Estimate USD -102.2 Million
Express News | Blueprint Medicines Q1 Basic EPS USD 1.45
Express News | Blueprint Medicines Q1 Operating Expenses USD 174,939,174.939 Million
Express News | Blueprint Medicines Q1 Net Income USD 89.136 Million Vs. Ibes Estimate USD -101.1 Million
Express News | Blueprint Medicines Q1 Product Revenue USD 92.525 Million
Express News | Blueprint Medicines Q1 EPS USD 1.4 Vs. Ibes Estimate USD -1.66
Blueprint Medicines 1Q Rev $96.1M >BPMC
Blueprint Medicines 1Q Rev $96.1M >BPMC
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersPulmonx (NASDAQ:LUNG) shares rose 29.5% to $10.0 during Wednesday's after-market session. The market value of their outstanding shares is at $388.1 million. The company's, Q1 earnings came out
Blueprint Medicines Q1 2024 Earnings Preview
Analysis
Price Target
No Data
